. 2024 Feb 8;39(2):127–136. doi: 10.3233/CBM-230040

Table 3.

Univariable and multivariable analysis in patients with gynecological malignant tumor for OS

Clinicopathologic factors	Univariable analysis			Multivariable analysis
	HR	95% CI	$P$ value	HR	95% CI	$P$ value
Age	3.964	1.885–8.336	$<$ 0.001	2.847	1.108–7.32	$<$ 0.05
Menopause	4.362	1.518–12.536	$<$ 0.01	2.729	0.737–10.109	0.133
BMI index	0.563	0.445–1.555	0.563
Albumin	0.113	0.048–0.267	$<$ 0.001	0.824	0.291–2.33	0.715
WBC	1.528	0.411–5.681	0.527
Hb	0.331	0.159–0.687	$<$ 0.01	0.648	0.278–1.51	0.315
MCV	1.701	0.470–6.156	0.418
CRP	11.918	4.842–29.334	$<$ 0.001	7.644	2.215–26.374	0.001
ALT	1.166	0.157–8.654	0.881
CA125	9.055	3.144–26.075	$<$ 0.001	5.445	1.365–21.727	$<$ 0.05
CEA	3.917	1.780–8.620	0.001	4.492	1.759–11.471	$<$ 0.05
AFP	2.814	0.655–12.086	0.164
CA153	4.601	2.212–9.572	$<$ 0.001	1.564	0.637–3.84	0.329
Ferritin	2.72	1.324–5.590	$<$ 0.01	0.792	0.351–1.787	0.574
Lymphatic metastasis	4.795	2.261–10.166	$<$ 0.001	1.022	0.359–2.909	0.968
Ascites	6.915	3.192–14.979	$<$ 0.001	1.048	0.359–3.056	0.932
Tumor size	2.201	1.016–4.766	$<$ 0.05	0.395	0.154–1.012	0.053
FIGO stage	2.989	2.058–4.342	$<$ 0.001	1.235	0.301–5.074	0.77

OS: overall survival; HR, hazard ratio; CI: confidence interval; BMI, body mass index; ALB, albumin; WBC, white blood cell; Hb, hemoglobin; MCV, mean corpuscular volume; CRP, C-reactive protein; ALT, alanine aminotransferase; CA125, cancer antigen 125; CEA, carcinoembryonic antigen; AFP, alpha fetoprotein; CA153, cancer antigen 153; FIGO, Inter-national Federation of Gynecology and Obstetrics.